Danaher Corporation $DHR Shares Purchased by Bullock Wealth Management Group

Bullock Wealth Management Group raised its stake in shares of Danaher Corporation (NYSE:DHR) by 45,050.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,515 shares of the conglomerate’s stock after buying an additional 4,505 shares during the quarter. Bullock Wealth Management Group’s holdings in Danaher were worth $1,000,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. EP Wealth Advisors LLC acquired a new position in shares of Danaher in the second quarter valued at approximately $3,807,000. Puzo Michael J acquired a new stake in Danaher during the second quarter worth approximately $8,624,000. First Nebraska Trust Co purchased a new stake in Danaher in the 2nd quarter worth approximately $14,106,000. Madison Asset Management LLC purchased a new stake in Danaher in the 2nd quarter worth approximately $85,451,000. Finally, Colton Groome Financial Advisors LLC acquired a new position in Danaher in the 3rd quarter valued at $592,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 1.2%

Shares of NYSE DHR traded up $2.69 during trading on Friday, hitting $220.15. 3,934,329 shares of the company traded hands, compared to its average volume of 4,457,726. The firm has a market capitalization of $154.76 billion, a P/E ratio of 39.10, a P/E/G ratio of 2.72 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The company has a 50-day moving average price of $210.88 and a 200-day moving average price of $194.44. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80.

Danaher (NYSE:DHR) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period last year, the company posted $0.77 EPS. The business’s quarterly revenue was up 5.5% on a year-over-year basis. On average, equities analysts predict that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is 28.42%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent analyst reports. UBS Group began coverage on Danaher in a research note on Wednesday, September 9th. They set a “buy” rating and a $250.00 price target on the stock. Royal Bank Of Canada upped their target price on Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a research note on Monday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $240.00 target price on shares of Danaher in a research report on Wednesday, July 22nd. Stifel Nicolaus lowered their price target on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. Finally, The Goldman Sachs Group upped their price objective on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $235.23.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.